Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

2.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

3.

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R.

Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992.

4.

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY.

Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.

PMID:
27450722
5.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R.

Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.

6.

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.

Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R.

Sci Rep. 2016 Apr 15;6:24578. doi: 10.1038/srep24578.

7.

FAK and paxillin, two potential targets in pancreatic cancer.

Kanteti R, Batra SK, Lennon FE, Salgia R.

Oncotarget. 2016 May 24;7(21):31586-601. doi: 10.18632/oncotarget.8040. Review.

8.

C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.

Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R.

Cancer Biol Ther. 2016;17(1):91-103. doi: 10.1080/15384047.2015.1108495.

9.

Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy.

Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R.

Nanomedicine. 2015 Nov;11(8):1971-4. doi: 10.1016/j.nano.2015.07.014. Epub 2015 Aug 15.

10.

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.

Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill PS, Salgia R.

Sci Rep. 2015 Jun 15;5:10641. doi: 10.1038/srep10641.

11.

MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.

Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R.

PLoS One. 2014 Sep 15;9(9):e105919. doi: 10.1371/journal.pone.0105919. eCollection 2014.

12.

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.

Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R.

BMC Cancer. 2014 Mar 14;14:185. doi: 10.1186/1471-2407-14-185.

13.

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R.

Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.

14.

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.

Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R.

J Carcinog. 2013 Oct 28;12:20. doi: 10.4103/1477-3163.120632. eCollection 2013.

15.

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R.

PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013.

16.

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR.

J Clin Oncol. 2013 Jun 1;31(16):e254-8. doi: 10.1200/JCO.2012.46.4289. Epub 2013 Apr 22. No abstract available.

17.

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.

18.

Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.

Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V.

PLoS One. 2012;7(9):e45330. doi: 10.1371/journal.pone.0045330. Epub 2012 Sep 17.

19.

The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization.

Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, Salgia R, Wang YC.

BMC Cancer. 2012 Jun 12;12:235. doi: 10.1186/1471-2407-12-235.

20.

Differential expression of RON in small and non-small cell lung cancers.

Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R.

Genes Chromosomes Cancer. 2012 Sep;51(9):841-51. doi: 10.1002/gcc.21968. Epub 2012 May 14.

PMID:
22585712
21.

Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW.

Int J Gynecol Pathol. 2012 Jan;31(1):15-24. doi: 10.1097/PGP.0b013e318220ba16.

22.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R.

J Clin Bioinforma. 2011 Feb 28;1(8):1-11. doi: 10.1186/2043-9113-1-8.

23.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R.

Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1.

24.

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.

Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R.

J Carcinog. 2011 Mar 3;10:4. doi: 10.4103/1477-3163.77274.

25.

Generation of comprehensive thoracic oncology database--tool for translational research.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R.

J Vis Exp. 2011 Jan 22;(47). pii: 2414. doi: 10.3791/2414.

26.

Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.

Liu W, He L, Ramírez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ.

Cancer Res. 2011 Apr 1;71(7):2423-7. doi: 10.1158/0008-5472.CAN-10-2689. Epub 2011 Feb 3.

27.

Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.

Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R.

Drugs Future. 2011 Feb;36(2):91-99.

28.

Anomalous coronary supply from right internal mammary artery.

Venkata NK, Vedangi RB, Chinta PR, Kanteti RM.

Eur J Cardiothorac Surg. 2011 Mar;39(3):417. doi: 10.1016/j.ejcts.2010.06.037. Epub 2010 Aug 30. No abstract available.

PMID:
20801053
29.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R.

J Biol Chem. 2010 Jun 11;285(24):18575-85. doi: 10.1074/jbc.M109.075085. Epub 2010 Apr 1.

30.

CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R.

PLoS One. 2010 Jan 29;5(1):e8972. doi: 10.1371/journal.pone.0008972. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/940edb14-522e-4f38-b6c4-7557e9a13d15. Hsu, Han-Shui [added].

31.
32.

Ethnic differences and functional analysis of MET mutations in lung cancer.

Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R.

Clin Cancer Res. 2009 Sep 15;15(18):5714-23. doi: 10.1158/1078-0432.CCR-09-0070. Epub 2009 Sep 1.

33.

Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin.

Bellmeyer A, Cotton C, Kanteti R, Koutsouris A, Viswanathan VK, Hecht G.

Am J Physiol Gastrointest Liver Physiol. 2009 Sep;297(3):G576-81. doi: 10.1152/ajpgi.00050.2009. Epub 2009 Jun 25.

34.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R.

Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.

35.

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R.

Lab Invest. 2009 Mar;89(3):301-14. doi: 10.1038/labinvest.2008.168. Epub 2009 Jan 12.

36.

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R.

Cancer Res. 2008 Jan 1;68(1):132-42. doi: 10.1158/0008-5472.CAN-07-1998.

37.

Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells.

Sharma R, Tesfay S, Tomson FL, Kanteti RP, Viswanathan VK, Hecht G.

Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G685-94. Epub 2005 Dec 1.

38.

Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier.

Tomson FL, Viswanathan VK, Kanack KJ, Kanteti RP, Straub KV, Menet M, Kaper JB, Hecht G.

Mol Microbiol. 2005 Apr;56(2):447-64.

39.

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP.

Blood. 2001 Oct 1;98(7):2059-64.

40.
41.

High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma.

McCann JC, Kanteti R, Shilepsky B, Miller KB, Sweet M, Schenkein DP.

Biol Blood Marrow Transplant. 1996 Feb;2(1):37-43.

PMID:
9078353

Supplemental Content

Loading ...
Support Center